Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection

Abstract

BACKGROUNDNaturally acquired immunity to malaria is incompletely understood. We used controlled human malaria infection (CHMI) to study the impact of past exposure on malaria in Kenyan adults in relation to infection with a non-Kenyan parasite strain.METHODSWe administered 3.2 × 103 aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (Sanaria PfSPZ Challenge, NF54 West African strain) by direct venous inoculation and undertook clinical monitoring and serial quantitative PCR (qPCR) of the 18S ribosomal RNA gene. The study endpoint was met when parasitemia reached 500 or more parasites per μL blood, clinically important symptoms were seen, or at 21 days after inoculation. All volunteers received antimalarial drug treatment upon meeting the endpoint.RESULTSOne hundred and sixty-one volunteers underwent CHMI between August 4, 2016, and February 14, 2018. CHMI was well tolerated, with no severe or serious adverse events. Nineteen volunteers (11.8%) were excluded from the analysis based on detection of antimalarial drugs above the minimal inhibitory concentration or parasites genotyped as non-NF54. Of the 142 volunteers who were eligible for analysis, 26 (18.3%) had febrile symptoms and were treated; 30 (21.1%) reached 500 or more parasites per μL and were treated; 53 (37.3%) had parasitemia without meeting thresholds for treatment; and 33 (23.2%) remained qPCR negative.CONCLUSIONWe found that past exposure to malaria, as evidenced by location of residence, in some Kenyan adults can completely suppress in vivo growth of a parasite strain originating from outside Kenya.TRIAL REGISTRATIONClinicalTrials.gov NCT02739763.FUNDINGWellcome Trust.

Keywords: Clinical Trials; Infectious disease; Malaria; Parasitology.

Conflict of interest statement

Conflict of interest: PFB and members of the CHMI-SIKA Study Team (Y Abebe, SLH, ERJ, TLR, and BKLS; see Supplemental Acknowledgments) are salaried, full-time employees of Sanaria, the manufacturer of Sanaria PfSPZ Challenge.

Figures

Figure 1. Study design and volunteer eligibility and enrollment for CHMI.

1One volunteer was both HIV and hepatitis B positive. 2Volunteers were assessed in the fourth quarter of 2017 but were not enrolled for CHMI due to national security reasons. *Volunteers were deemed to have completed CHMI if they had received endpoint treatment. qPCR outcomes are presented for 142 volunteers after exclusions for parasite genotype and antimalarial drug levels.

Figure 2. qPCR outcome based on volunteer location.

Blood samples from C+8 (C+7.5 for Nairobi) onward after inoculation to determine parasitemia from (A) Nairobi (n = 27), (B) Kilifi North (n = 34), (C) Kilifi South (n = 93), and (D) Ahero (n = 15). Parasitemia was determined by asexual 18S ribosomal RNA gene qPCR done in Kilifi. Blue lines represent individuals who required treatment and reached treatment threshold (reached DoT). Green lines represent individuals who did not meet criteria for treatment threshold but were qPCR positive. Orange lines represent individuals who were qPCR negative throughout monitoring. Red dots denote individuals who were febrile and met treatment criteria.